Predict your next investment

Perspectum company logo
SOFTWARE (NON-INTERNET/MOBILE) | Healthcare Software
perspectum.com

See what CB Insights has to offer

Founded Year

2012

Stage

Unattributed VC | Alive

Total Raised

$36.25M

Last Raised

$36M | 2 yrs ago

About Perspectum

Perspectum is a provider of digital technologies that help clinicians provide better care for patients with liver disease. The company's work focuses on the detection and accurate, quantitative measurement of liver, gall bladder, and pacreatic disease.

Perspectum Headquarter Location

Gemini One 5520 John Smith Drive

Oxford, England, OX4 2LL,

United Kingdom

+44 (0)1865 655 343

Latest Perspectum News

Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health

Nov 1, 2021

11/01/2021 | 08:31am EDT Message : Partnership Combines Imaging and Functional Assessment for Clinical Research Perspectum and HepQuant are proud to announce a strategic business partnership to provide seamless delivery of HepQuant’s liver function assessment technology via Perspectum’s Contract Research Organization (CRO) services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211101005151/en/ The collaboration will enable pharmaceutical companies sponsoring clinical trials for liver disease, including liver cirrhosis, nonalcoholic steatohepatitis (NASH), autoimmune liver diseases and liver cancer to receive both imaging and function testing expertise from Perspectum’s Pharma Solutions. A combined functional and imaging analysis platform could provide the next generation assessment that is needed for a complete picture of liver health. “We are pleased to collaborate with HepQuant,” said Dr. Rajarshi Banerjee, Chief Executive Officer of Perspectum. “We have witnessed the unmet need in liver function testing and recognize HepQuant as a leader in the noninvasive functional assessment of the liver. Alongside our best-in-class quantitative imaging platform, we believe collaborating to improve how we diagnose, treat, and monitor chronic liver disease, cirrhosis and liver cancer will best serve the vast and growing number of people suffering from these diseases.” The partnership will also include investigation of clinical utility of combining function and imaging modalities in potential clinical pathways for future diagnosis and treatment in liver diseases. A complete picture of liver health could be useful to payers making decisions regarding the coverage for current and future treatments, particularly of fatty liver and fibrotic disease. “HepQuant believes combinations of new non-invasive testing platforms could improve the safety and reliability of assessment of the patient with liver disease,” said Dr. Gregory T. Everson, Founder and Chief Executive Officer of HepQuant. “Function is a key element of this comprehensive assessment. This functional assessment coupled with Perspectum’s LiverMultiScan yields a complete picture of liver health with a goal to improve management of patients, both in clinical trials and in the clinic.” About Perspectum Perspectum, a global medical technology company with offices in the U.K., the U.S. and Singapore, delivers leading digital technologies that help clinicians provide better care for patients with chronic metabolic diseases, multi-organ pathologies and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers and technologists, Perspectum offers a way to manage complex health problems at scale. About HepQuant Headquartered in Denver, Colorado, HepQuant, LLC, is a privately-held diagnostic company. HepQuant’s products are investigational combination drug and in-vitro diagnostic devices and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA guidelines for investigational device exemptions (IDEs). For additional information, visit www.hepquant.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005151/en/ © Business Wire 2021

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Perspectum

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Perspectum in 1 CB Insights research brief, most recently on Aug 13, 2020.

Expert Collections containing Perspectum

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Perspectum is included in 6 Expert Collections, including Medical Devices.

M

Medical Devices

11,412 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Conference Exhibitors

5,302 items

H

Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Diabetes

1,750 items

D

Digital Health 150

150 items

The winners of the second annual CB Insights Digital Health 150.

Perspectum Patents

Perspectum has filed 5 patents.

The 3 most popular patent topics include:

  • Magnetic resonance imaging
  • Medical imaging
  • Neuroimaging
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/28/2017

11/24/2020

Hepatology, Digestive system surgery, Digestive system, Digestive system procedures, Endoscopy

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/28/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/24/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Hepatology, Digestive system surgery, Digestive system, Digestive system procedures, Endoscopy

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Perspectum Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Perspectum Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.